INCIDENCE OF THROMBOEMBOLIC EVENTS IN THE TOFACITINIB RHEUMATOID ARTHRITIS, PSORIASIS, PSORIATIC ARTHRITIS AND ULCERATIVE COLITIS DEVELOPMENT PROGRAMMES

被引：3

作者：

Mease, P. J. ^{[1
,2
]}

Kremer, J. ^{[3
]}

Cohen, S. ^{[4
]}

Curtis, J. R. ^{[5
]}

Charles-Schoeman, C. ^{[6
]}

Loftus, E. V., Jr. ^{[7
]}

Greenberg, J. ^{[8
]}

Palmetto, N. ^{[7
]}

Kanik, K. S. ^{[10
]}

Graham, D. ^{[10
]}

Wang, C. ^{[10
]}

Biswas, P. ^{[9
]}

Chan, G. ^{[11
]}

DeMasi, R. ^{[11
]}

Valdez, H. ^{[9
]}

Hendrikx, T. ^{[11
]}

Jones, T. V. ^{[11
]}

机构：

[1] Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Seattle, WA 98195 USA

[3] Albany Med Coll & Ctr Rheumatol, Albany, NY USA

[4] Metroplex Clin Res Ctr, Dallas, TX USA

[5] Univ Alabama Birmingham, Birmingham, AL USA

[6] Univ Calif Los Angeles, Los Angeles, CA USA

[7] Mayo Clin, Rochester, MN USA

[8] Corrona LLC, Southborough, MA USA

[9] Pfizer Inc, New York, NY USA

[10] Pfizer Inc, Groton, CT 06340 USA

[11] Pfizer Inc, Collegeville, PA USA

来源：

关键词：

D O I：

10.1136/annrheumdis-2018-eular.3048

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SAT0243

引用

页码：983 / 983

页数：1